“With clearly demonstrated success in detecting differential toxicity in ADCs, our NAMkind models are now well-established at the cutting edge of the field,” said Keith Murphy, VivoSim’s Executive ...

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE)-- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, ...

With three dynamic tracks covering discovery, preclinical, clinical, and CMC, plus exclusive seminar days on ADC fundamentals and Bispecific ADCs, this guide ensures you gain critical insights and ...

Whether you're exploring emerging trends, novel payloads, or streamlined manufacturing strategies, this guide ensures you stay ahead in the ever-evolving ADC landscape. Download your copy now and ...

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE)- ...